Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges
Year: 2015
Type: article
Study design: Observational Study
Abstract: INTRODUCTION: This study investigated the comparability of potential Alzheimer's disease (AD) biomarkers across blood fractions and assay platforms. METHODS: Nonfasting serum and plasma samples from 300 participants (150 AD patients and 150 controls) were analyzed. Proteomic markers were obtained via electrochemiluminescence or Luminex technology. Comparisons were conducted via Pearson correlations. The relative importance of proteins within an AD diagnostic profile was examined using random forest importance plots. RESULTS: On the Meso Scale Discovery multiplex platform, 10 of the 21 markers shared >50% of the variance across blood fractions (serum amyloid A R(2) = 0.99, interleukin (IL)10 R(2) = 0.95, fatty acid-binding protein (FABP) R(2) = 0.94, I309 R(2) = 0.94, IL-5 R(2) = 0.94, IL-6 R(2) = 0.94, eotaxin3 R(2) = 0.91, IL-18 R(2) = 0.87, soluble tumor necrosis factor receptor 1 R(2) = 0.85, and pancreatic polypeptide R(2) = 0.81). When examining protein concentrations across platforms, only five markers shared >50% of the variance (beta 2 microglobulin R(2) = 0.92, IL-18 R(2) = 0.80, factor VII R(2) = 0.78, CRP R(2) = 0.74, and FABP R(2) = 0.70). DISCUSSION: The current findings highlight the importance of considering blood fractions and assay platforms when searching for AD relevant biomarkers.
Authors: Sid E. O'Bryant, Simone Lista, Robert A. Rissman, Melissa Edwards, Fan Zhang, James Hall, Henrik Zetterberg, Simon Lovestone, Veer Gupta, Neill Graff‐Radford, Ralph Martins, Andreas Jeromin, Stephen Waring, Esther Oh, Mitchel Kling, Laura D. Baker, Harald Hampel, ISTAART Blood Based Biomarker Professional Interest Area
Institutions: University of North Texas Health Science Center, Pitié-Salpêtrière Hospital, AXA Research Fund, Institut du Cerveau, Université Pierre-et-Marie-Curie, University of California San Diego, University of North Texas, UCL Queen Square Institute of Neurology, University College London, University of Gothenburg, University of Oxford, Edith Cowan University, Mayo Clinic, Mayo Clinic in Florida, Quanterix (United States), Essentia Health, Johns Hopkins University, Johns Hopkins Medicine, Philadelphia VA Medical Center, University of Pennsylvania, Wake Forest University Health Sciences, Wake Forest University
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,540
Awards: G2298519484, Neurobiology of Alzheimer's Disease and Aging, Alzheimer's Disease Cooperative Study (ADCS), Stress and CRF Signaling in Alzheimer?s Disease Pathogenesis, A Blood-Based Screening Tool for Alzheimer's Disease, Polytherapy for AD: Combining Gamma-secretase Modulation and CRFR1 Antagonism, G9000106143
OpenAlex ID: W2200373373
